Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
A preliminary report depicted confusion in the cockpit shortly before an Air India jetliner crashed, killing 260 people last month, after the plane's engine fuel cutoff switches almost simultaneously flipped, starving the engines of fuel.
US President Donald Trump defended the state and federal response to deadly flash flooding in Texas on Friday as he visited the stricken Hill Country region, where at least 120 people, including dozens of children, perished a week ago.
Russia pounded Ukraine with hundreds of drones and dozens of missiles on Saturday, in the fourth major attack this month, targeting western cities and killing at least two people in Chernivtsi on the border with Romania.
Thirty Kurdistan Workers Party (PKK) fighters burned their weapons at the mouth of a cave in northern Iraq on Friday, marking a symbolic but significant step toward ending a decades-long armed conflict against Turkey.